JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles
MINDTELL TECH (08611) intends to issue convertible bonds in the amount of HKD 28.6 million to the executive director, Zhang Rongxuan.
US Stock Market Move | Ford Motor Company (F.US) surged 10% in Q3, with profits and sales exceeding expectations.
DYNAGREEN ENV (01330) achieved a electricity output of 1.328 billion degrees in the third quarter.
MINDTELL TECH (08611) intends to issue convertible bonds in the amount of HKD 28.6 million to the executive director, Zhang Rongxuan.
US Stock Market Move | Ford Motor Company (F.US) surged 10% in Q3, with profits and sales exceeding expectations.
DYNAGREEN ENV (01330) achieved a electricity output of 1.328 billion degrees in the third quarter.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
